Read our COVID-19 research and news.

Webinar Technology

Culturing Human Cells: Optimizing Growth Conditions for Immunotherapy

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Culturing Human Cells: Optimizing Growth Conditions for Immunotherapy

Recorded 01 October 2014

Speakers

Downloads

Growing human cells in culture for research is one thing, but the isolation and culture of high-quality cells that will be re-injected back into the donor is quite another. Manipulation and expansion of cells in a clinical setting carries its own unique requirements and complications. Growth and survival needs to be optimized and quality control is paramount. Often only a single opportunity for successful treatment is possible, so chances of success need to be maximized in all respects, including high-yield isolation of good quality cells from patients, cell culture conditions, cell characterization, and reperfusion back into patients. During this webinar, we will broadly examine the process of immunotherapy as well as examine in more detail some of the most critical steps along the pathway to generating a therapeutic dose of modified cells.

During the webinar, the speakers will:

  • Highlight how immunotherapy is currently being applied in the clinic and those factors important to generating high-quality cells
  • Discuss the importance of perfusion to achieving high cell yield and its effect on cell markers and characteristics
  • Focus on optimization of culture conditions when generating cells for reperfusion into patients
  • Answer your questions live during the webinar!
     

To learn more about products or technologies related to this webinar, go to: www.gelifesciences.com/xuri

Speaker bios

Laurence J. N. Cooper, M.D., Ph.D.

MD Anderson Cancer Center
Houston, TX

Dr. Cooper serves as chief executive officer of ZIOPHARM Oncology and maintains a position as a visiting scientist at MD Anderson Cancer Center (MDACC). He joined ZIOPHARM in 2015, following MDACC’s licensing agreement with Intrexon and ZIOPHARM. Dr. Cooper joined MDACC in 2006 as section chief of cell therapy at the Children’s Cancer Hospital, where he cared for children undergoing bone marrow transplantation and led scientific efforts to develop new treatment approaches that pair genetic engineering with immunotherapies. Dr. Cooper has coauthored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under investigational new drug applications using infused T cells and natural killer (NK) cells. He is directing the first gene therapy protocols using modified chimeric antigen receptor T (CAR T) cells based upon the Sleeping Beauty transposon system, and has helped develop clinical-grade artificial antigen-presenting cells for numerically expanding and activating immune cells.

Michelle Janas, Ph.D.

GE Healthcare
Cardiff, Wales

Dr. Janas is trained as an immunologist, primarily in the development of the adaptive immune system. She completed her Ph.D. in 2000 at the Walter and Eliza Hall Institute in Parkville, Australia, after which she joined the Perth-based company, Ozgene. In 2002, Dr. Janas pursued postdoctoral training at the Queensland Institute of Medical Research in Brisbane and the Babraham Institute in Cambridge, United Kingdom, before becoming a senior scientist for cell therapy technologies at GE’s Cardiff, Wales site. In her current role at GE Healthcare, she is focused on developing solutions that allow cell therapies to become a mainstream treatment option.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here